A drop in the prices of non-human primates (NHPs) in China indicates a post-pandemic slowdown in Chinese drug development, according to a report in the Financial Times. The price of NHPs in China increased from $4,000 per animal in 2019 to $26,000 in 2022, but by the end of 2023, had fallen to $11,000. The […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!